You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
FRUZAQLA®(呋喹替尼/fruquintinib)銷售額超過2億美元,和黃醫藥(00013.HK)收到武田2千萬美元里程碑付款
格隆匯 10-31 16:48

格隆匯10月31日丨和黃醫藥(00013.HK)今日,宣佈因FRUZAQLA® (呋喹替尼)用於治療轉移性結直腸癌的銷售額超過2億美元觸發,將收到來自合作伙伴武田 (TSE :4502/ NYSE :TAK)的2千萬美元里程碑付款。結直腸癌是美國第二大常見癌症死亡原因。每年,美國、歐洲和日本約新增84 萬例結直腸癌新症。

截至2024年9月的九個月內,武田實現FRUZAQLA®淨銷售額2.03億美元。該筆 2千萬美元的付款將是和黃醫藥收到的首個商業里程碑付款。武田擁有在中國內地、香港和澳門以外進一步開發、商業化和生產呋喹替尼的全球獨家許可,並以商品名FRUZAQLA®上市銷售。呋喹替尼2023年11月在美國 、2024年6月在歐盟 、2024年8月在瑞士 、2024年9月在加拿大、日本和英國 ,以及2024年10月在阿根廷、澳洲和新加坡獲批。在其他多個國家和地區的監管申請亦在進行中。

和黃醫藥首席執行官兼首席科學官蘇慰國博士表示:"實現2億美元的銷售額證明了武田在全球範圍內推出產品上市的商業實力、呋喹替尼的臨牀獲益以及我們通過合作推動產品在中國境外商業化戰略的成功。此次收到2千萬美元里程碑付款將進一步鞏固我們的資產負債表,我們期待擴展呋喹替尼用更多新的適應症,以及在更廣泛的管線中推動我們的全球合作戰略。"

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account